I think you misunderstood my question. I was referring to Celgene's more productive partnership discussions with other companies - not the chf product.
Partnerships that involve much larger financial consideration than what is on the table with Mesoblast. Have a look, for example, at the size and commitment of the deal Celgene struck up with Juno, with not anywhere near the lengthy discussion we are supposed to think is going on with Mesoblast.
No matter, you're telling me these complex iterations now involve chf.
Earlier in the year you were explaining all the iterations and complexity were around other products; RA, agvhd and Crohn's.
So now you are saying they've stopped iterating round the inflammatory conditions, and chf is now what's making the wheels spin.
To be honest, it sounds like you are sort of making it up as you go along.
If MSB is to be removed from S&P ASX 200...., page-189
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
-0.010(0.76%) |
Mkt cap ! $1.495B | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.33 | $1.28 | $1.819M | 1.396M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 29972 | $1.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 2008 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |